Menu

Medical

Inovalon and MDLIVE Bring Real-Time Advanced Analytics to Telemedicine Marketplace

,

On-Demand, Real-Time Patient Insights and Analytics to Drive High-Value Impact for Telemedicine Visits BOWIE, Md, (Sept. 12, 2016) — Inovalon (NASDAQ: INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced a multi-year agreement with MDLIVE, a leading telehealth platform provider, to provide on-demand, real-time patient […]

Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North America

, , ,

Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications DUBLIN, Ohio–(BUSINESS WIRE)–Sep. 6, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has executed a Letter of Intent (“LOI”) with Cardinal Health, Inc. (NYSE:CAH) for the sale of all rights, title and interest to Navidea’s Lymphoseek product for all FDA-approved, pending and […]

Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy

, , , ,

TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status Data will be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) September 1, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results for TECENTRIQ® from the Phase III study, OAK. The study met […]

Fighting Prescription Drug Misuse through Community Programs: Cardinal Health Foundation Announces Generation Rx Medication Disposal Grants

, , ,

DUBLIN, Ohio, Aug. 31, 2016 /PRNewswire/ — Non-profit organizations across the country were awarded grants from the Cardinal Health Foundation to help fight prescription drug misuse by improving their communities’ medication disposal programs. According to the 2013 National Survey on Drug Use and Health, nearly 70% of those who misuse prescription drugs get them from […]

XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer

, , , ,

XALKORI is the first and only approved biomarker-driven therapy for ROS1-positive advanced NSCLC in the EU Wednesday, August 31, 2016 – “The European Commission’s decision to approve XALKORI for ROS1-positive advanced NSCLC represents an important milestone for patients who previously had limited treatment options” Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved […]

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

, , , ,

ODYSSEY ESCAPE data concurrently published in the European Heart Journal Paris, France and Tarrytown, New York – August 29, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous […]

Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product

, , ,

HERTFORDSHIRE, England and PITTSBURGH, Aug. 29, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, […]

Pfizer To Acquire Medivation

, , , ,

Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth […]

Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA

, , , ,

Transaction formally closed in the first quarter of 2016 / Laboratory and office space will be near Kendall Square in Cambridge, MA / Hiring is underway and efforts have begun on initial programs in hematology and ophthalmology Leverkusen, Germany and Basel, Switzerland, August 19, 2016 – Casebia Therapeutics, the joint venture founded by Bayer and […]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

, , , ,

August 8, 2016 KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or […]

«‹ 16 17 18 19›»